Cardiol Therapeutics Inc. Class A (CRDL)
NASDAQ: CRDLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CRDL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $110.14M
- EPS (TTM)
- -$0.24
- Dividend yield
- None
- 52-week range
- 0.8417 – 2.34
- Day range
- 0.8417 – 0.8952
- Volume / Avg
- 552.97K / 1.20M
- Beta
- —
- Shares outstanding
- 127.69M
52-week range
CRDL stock today
Cardiol Therapeutics (CRDL) closed at $0.8626 on Nov 20, down 2.28% (-$0.0201), versus the S&P 500's 3.70% decline. Trading was light, with 552.97K shares changing hands, about 46% of the average daily volume. Shares are 63.1% below their 52-week high of $2.34, set on Sep 9, 2026 and 2.5% above the 52-week low of $0.8417, near the bottom of the past year's range.
CRDL is down 9.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 11.3%. Cardiol Therapeutics has posted a net loss over the last twelve months (EPS of -$0.24), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Cardiol Therapeutics
Company profileCardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. David G. Elsley MBA
- Headquarters
- Oakville, ON
- Employees
- 18
- Website
- cardiolrx.com
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$8.41+874.96%
- Strong buy 2
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.09 vs $-0.06
- Surprise
- -50.00%
CRDL news
All CRDL newsCardiol Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| FATEFate Therapeutics Inc. | 0.919 | -9.01% | $111.82M | vs CRDL |
| ARMPArmata Pharmaceuticals Inc. | 3.03 | +1.68% | $112.69M | vs CRDL |
| ENGNenGene Therapeutics Inc. | 1.74 | -1.14% | $116.61M | vs CRDL |
| IVVDInvivyd Inc. | 0.4127 | -7.45% | $122.01M | vs CRDL |
| MOLNMolecular Partners AG ADR | 2.53 | -5.25% | $96.80M | vs CRDL |
| HUMAHumacyte Inc. | 0.4454 | -17.90% | $123.73M | vs CRDL |
| IPHAInnate Pharma S.A. ADS | 0.8634 | -8.14% | $96.44M | vs CRDL |
| CMPXCompass Therapeutics Inc. | 0.6882 | +1.43% | $123.94M | vs CRDL |
Indexes, lists and sector
Cardiol Therapeutics stock FAQ
What is Cardiol Therapeutics's stock price today?
CRDL last traded at $0.8626 as of Nov 20, 4:00 PM EST, down 2.28% on the day. Prices are delayed at least 15 minutes.
Who is Cardiol Therapeutics's CEO?
Mr. David G. Elsley MBA is the chief executive officer of Cardiol Therapeutics Inc. Class A, which has about 18 employees.
What is the CRDL 52-week high?
The 52-week high for CRDL is $2.34 and the 52-week low is $0.8417. The stock is currently 63.1% below its high.